Zika Virus: A Comprehensive Review of Virology, Clinical Manifestations, Epidemiology, Diagnosis, and Management

Abstract

Zika virus (ZIKV), a mosquito-borne flavivirus, has emerged as a significant global health threat following widespread outbreaks in Americas and Pacific regions. Initially isolated in Uganda in 1947, ZIKV remained relatively obscure until its explosive emergence in Brazil in 2015, which was linked to surge in congenital malformations and neurological disorders. Transmitted primarily by Aedes aegypti mosquitoes, the virus is capable of sexual, vertical (mother-to-child), and blood transfusion-related transmission. While most infections are asymptomatic/mild, ZIKV has gained attention due to its severe complications, including Congenital Zika Syndrome (CZS) and Guillain-Barré Syndrome (GBS). The pathogenesis involves neurotropism, placental invasion, and immune evasion, leading to significant fetal and neurological damage. Diagnosis relies on molecular techniques like reverse transcription polymerase chain reaction (RT-PCR) and serological assays; however, cross-reactivity with other flaviviruses, particularly dengue, complicates interpretation. Currently, there is no specific antiviral treatment, and management is supportive, with a focus on maternal and neonatal care. Preventive strategies include vector control, personal protection, and travel advisories. Although several vaccine candidates are under investigation, none have yet received regulatory approval for widespread use. This review aims to provide a comprehensive analysis of Zika virus biology, clinical features, transmission dynamics, diagnostic modalities, therapeutic approaches, and prevention strategies. Emphasis is placed on public health impact, challenges in surveillance and control, and future directions for research and vaccine development. Given the potential for re-emergence and congenital implications, ZIKV remains a priority pathogen for global health monitoring and intervention.

Keywords

Introduction

Zika virus (ZIKV), a flavivirus first identified in 1947 in Uganda, has evolved from a relatively obscure pathogen into a significant global public health concern. While early outbreaks were sporadic and mild, major epidemics in Micronesia (2007), French Polynesia (2013), and Brazil (2015) revealed its potential for widespread transmission and severe complications. Primarily spread by Aedes mosquitoes—especially Aedes aegypti and Aedes albopictus—ZIKV is also notable for non-vector transmission routes, including sexual contact, vertical (mother-to-fetus) transmission, and blood transfusion. Clinically, most ZIKV infections are asymptomatic. Symptomatic cases typically present with mild symptoms such as rash, fever, arthralgia, and  conjunctivitis^.[1] However, ZIKV gained international attention due to its association with serious neurological outcomes, particularly Congenital Zika Syndrome (CZS)—a constellation of birth defects including microcephaly and ocular abnormalities—and Guillain-Barré Syndrome (GBS) in adults. The 2015–2016 outbreak in Brazil prompted the World Health Organization to declare ZIKV a Public Health Emergency of International Concern. Despite intensified research efforts, significant challenges persist. Laboratory diagnosis is complicated by cross-reactivity with other flaviviruses like dengue. Moreover, there are no approved antiviral treatments or vaccines, though several candidates are in development. Current control efforts focus on vector management, public education, and protecting pregnant women. This review highlights ZIKV’s virology, transmission mechanisms, clinical impact, diagnostic limitations, and preventive strategies.^[2]

VIROLOGY AND MOLECULAR BIOLOGY:

Zika virus (ZIKV) is a single-stranded, positive-sense RNA virus within the Flavivirus genus of the Flaviviridae family, closely related to other notable arboviruses such as Dengue, Yellow Fever, and West Nile viruses. Its ~10.7 kb genome encodes a single polyprotein that is cleaved into three structural (C, prM, E) and seven non-structural (NS1–NS5) proteins. The envelope (E) protein is key to viral entry and the primary target of host neutralizing antibodies. ZIKV infects host cells via receptor-mediated endocytosis, with replication occurring in the cytoplasm, where NS proteins facilitate genome replication, protein processing, and immune evasion. Phylogenetic analyses classify ZIKV into two main lineages—African and Asian. The recent outbreaks in the Americas have been attributed to the Asian lineage, which exhibits enhanced neurovirulence and transplacental transmission potential. Specific mutations, particularly in the prM and NS1 genes, are believed to play a role in increased pathogenicity and fetal neurotropism. Detailed understanding of ZIKV’s molecular biology is critical for advancing antiviral drug development, diagnostic innovation, and vaccine design.^[3]

TRANSMISSION AND PATHOGENESIS:

Zika virus (ZIKV) is predominantly transmitted to humans via bites from infected Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus, which are also vectors for dengue and chikungunya viruses. These mosquitoes are most active during the daytime and thrive in densely populated environments. Once infected, mosquitoes can transmit the virus for life following a 10–14day extrinsic incubation period. Uniquely among arboviruses, ZIKV also spreads through non-vector routes, including sexual transmission (with prolonged viral persistence in semen), vertical transmission from mother to fetus, blood transfusions, and, rarely, laboratory exposure. Its capacity to cross the placental barrier and infect fetal neural tissues highlights its pronounced neurotropism and underpins the development of Congenital Zika Syndrome (CZS). ZIKV pathogenesis involves infection of various cell types, including neural progenitor cells, placental trophoblasts, and endothelial cells. The virus induces apoptosis, impairs neurodevelopment, and provokes inflammatory responses. Key molecular mechanisms include suppression of the interferon response, particularly via inhibition of STAT2 signaling, and upregulation of autophagy pathways. Understanding these transmission modes and molecular mechanisms is crucial for informing public health strategies, vaccine development, and clinical care for vulnerable populations, especially pregnant women.^[4]

EPIDEMIOLOGY:

Zika virus (ZIKV) was first identified in 1947 in Uganda and initially remained limited to sporadic human cases in Africa and Southeast Asia with minimal clinical impact. The virus gained epidemiological significance in the 21st century, beginning with a major outbreak in Yap Island, Micronesia, in 2007, followed by a larger epidemic in French Polynesia (2013–2014), where it was first associated with neurological complications such as Guillain-Barré Syndrome (GBS). The most impactful outbreak occurred in Brazil in 2015, where widespread transmission was linked to a surge in congenital anomalies, particularly microcephaly, leading the World Health Organization (WHO) to declare ZIKV a Public Health Emergency of International Concern (PHEIC) in 2016. Since then, over 84 countries and territories have reported local transmission. The global spread of ZIKV is facilitated by the wide distribution of Aedes mosquitoes—especially A. aegypti—and exacerbated by factors such as climate change, urbanization, global travel, and inadequate vector control. Surveillance efforts face challenges due to the high proportion of asymptomatic infections and diagnostic cross-reactivity with other flaviviruses. Ongoing global monitoring is critical to detect re-emergence and reduce future public health risks.^[5]

CLINICAL MANIFESTATIONS:

Zika virus (ZIKV) infection presents with a broad clinical spectrum, predominantly asymptomatic in 70–80% of cases, which hinders early detection and surveillance. When symptomatic, the illness is typically mild and self-limiting, with manifestations resembling other arboviral infections such as dengue and chikungunya. Common symptoms include low-grade fever, maculopapular rash, arthralgia, non-purulent conjunctivitis, myalgia, and headache, typically appearing 3–14 days post-exposure and resolving within a week. Despite its generally benign course in adults, ZIKV can lead to serious complications. Of particular concern is its neurotropism, which has been linked to Guillain-Barré Syndrome (GBS), characterized by progressive muscle weakness and potential respiratory compromise. Other reported neurological manifestations include encephalitis and meningoencephalitis, especially in immunocompromised individuals. The most severe outcomes occur in congenital infections. Congenital Zika Syndrome (CZS) results from vertical transmission during pregnancy, particularly in the first trimester, and includes features such as severe microcephaly, intracranial calcifications, ventriculomegaly, ocular defects, limb contractures, and developmental delays. Given the nonspecific clinical presentation and overlap with other flaviviruses, laboratory confirmation is essential, particularly in pregnant women, neonates, and patients with neurological symptoms, to ensure accurate diagnosis and appropriate clinical management.^[6]

DIAGNOSTIC MODALITIES:

Accurate diagnosis of Zika virus (ZIKV) infection is essential for effective clinical management, surveillance, and prevention of congenital transmission. Diagnosis is complicated by the virus’s typically mild symptoms and serological cross-reactivity with other flaviviruses, particularly dengue. The diagnostic gold standard during the acute phase is reverse transcription polymerase chain reaction (RT-PCR), which detects viral RNA in blood, urine, saliva, semen, or cerebrospinal fluid. RNA is most reliably detected in serum within the first 3–7 days of illness but may persist longer in urine and semen, extending the diagnostic window. Serological testing using IgM and IgG ELISAs is useful after the viremic phase but suffers from cross-reactivity, limiting specificity. To improve diagnostic accuracy, plaque reduction neutralization tests (PRNT) are employed to distinguish ZIKV from related flaviviruses by quantifying virus-specific neutralizing antibodies. In pregnant women, especially those exposed in endemic regions, a combination of molecular and serological testing is recommended. If fetal infection is suspected, amniocentesis with RT-PCR on amniotic fluid may be utilized. Advances such as real-time RT-PCR and multiplex assays have enhanced diagnostic sensitivity and specificity, yet significant barriers remain in low-resource settings due to cost and infrastructure limitations. The development of rapid, reliable point-of-care diagnostics remains a public health priority for timely detection and outbreak response.^[7]

MANAGEMENT AND TREATMENT:

There is currently no specific antiviral therapy for Zika virus (ZIKV) infection; management is primarily supportive. Most cases are mild and self-limiting, requiring rest, adequate hydration, and symptom relief, typically with acetaminophen. Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin are contraindicated until dengue is ruled out, due to hemorrhagic risk. Severe cases, especially those involving neurological complications such as Guillain-Barré Syndrome (GBS), may necessitate hospitalization, intravenous immunoglobulin (IVIG), respiratory support, and rehabilitative care. Pregnant women with ZIKV infection require close monitoring, including serial ultrasounds to assess fetal development. Infected neonates should undergo comprehensive neurological, auditory, and ophthalmologic evaluations, regardless of clinical presentation at birth. There are currently no approved vaccines or antiviral agents for ZIKV, although multiple candidates—such as DNA, mRNA, and inactivated vaccines—are in development. In the absence of targeted therapies, prevention remains the cornerstone of ZIKV control. Strategies include vector control, personal protective measures against mosquito exposure, public health education, and travel advisories for pregnant women. Early diagnosis, supportive care, and proactive prevention are essential to mitigate the impact of ZIKV infection.^[8]

PREVENTIVE STRATEGIES AND CONTROL MEASURES:

In the absence of an approved antiviral therapy or vaccine, prevention and control of Zika virus (ZIKV) primarily depend on reducing mosquito exposure and interrupting transmission, particularly among high-risk groups such as pregnant women. Vector control is the cornerstone of prevention and includes eliminating breeding sites, indoor residual spraying, and larvicide application. Sustained success requires community-based interventions focused on environmental management and public awareness. Personal protective measures—such as wearing long-sleeved clothing, using insect repellents (e.g., DEET or picaridin), and employing mosquito nets or screened enclosures—are especially important during daytime when Aedes mosquitoes are most active. Travel advisories are critical in preventing international spread, with pregnant women advised to avoid endemic regions. Returning travelers should practice safe sex or abstinence to prevent sexual transmission. Non-vector transmission prevention also includes screening of blood donations and implementing safety protocols in laboratories handling ZIKV. Although several vaccine candidates, including DNA, mRNA, and inactivated virus platforms, are in advanced development, none have been approved for general use. Effective ZIKV prevention demands integrated public health strategies, encompassing health education, community engagement, robust surveillance systems, and international collaboration to mitigate the global impact and prevent future outbreaks.^[9]

CURRENT RESEARCH AND FUTURE DIRECTIONS:

Ongoing Zika virus (ZIKV) research targets key gaps in diagnostics, therapeutics, vaccines, and pathogenesis. Vaccine candidates—including DNA, mRNA, inactivated, and live-attenuated platforms—are in clinical trials, though none are approved yet. Antiviral efforts focus on inhibitors of viral replication and drug repurposing. Molecular studies are uncovering mutations linked to neurovirulence and fetal transmission. Diagnostic advancements aim to improve sensitivity and specificity, especially in resource-limited settings. Future priorities include long-term monitoring of affected infants, novel vector control, and integrated surveillance. A multidisciplinary approach is vital to mitigate future outbreaks.^[10]

CONCLUSION:

Zika virus remains a global health concern due to its neurotropic nature and association with serious complications like Guillain-Barré Syndrome and Congenital Zika Syndrome. With no approved antiviral treatment or vaccine, prevention through vector control, public awareness, and travel precautions is essential. Ongoing research focuses on vaccine development, antiviral therapies, and improved diagnostic tools. Despite a decline in cases, the potential for re-emergence in endemic regions underscores the need for continued surveillance and preparedness. A coordinated, multidisciplinary approach is crucial to effectively manage Zika virus and reduce its long-term public health impact.

REFERENCES

1. Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev. 2016;29(3):487–524. doi:10.1128/CMR.00072-15.
2. Petersen LR, Jamie-son DJ, Powers AM, Hone-in MA. Zika Virus. N Engl J Med. 2016;374(16):1552–63. doi:10.1056/NEJMra1602113.
3. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis. 2016;16(7):e119–26. doi:10.1016/S1473-3099(16)30010-X.
4. Rasmussen SA, Jamie-son DJ, Hone-in MA, Petersen LR. Zika Virus and Birth Defects — Reviewing the Evidence for Causality. N Engl J Med. 2016;374(20):1981–7. doi:10.1056/NEJMsr1604338.
5. Mlakar J, Korva M, Tul N, Popovi? M, Poljšak-Prijatelj M, Mraz J, et al. Zika Virus Associated with Microcephaly. N Engl J Med. 2016;374(10):951–8. doi:10.1056/NEJMoa1600651.
6. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–9. doi:10.1016/S0140-6736(16)00562-6.
7. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 2016;130:69–80. doi:10.1016/j.antiviral.2016.03.010.
8. WHO. Zika virus outbreaks in the Americas. Wkly Epidemiol Rec. 2016;91(7):73–88. [Accessed via: https://www.who.int].
9. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika Virus Outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–43. doi:10.1056/NEJMoa0805715.
10. Haby MM, Pinart M, Elias V, Reveiz L. Prevalence of asymptomatic Zika virus infection: a systematic review. Bull World Health Organ. 2018;96(6):402–413D. doi:10.2471/BLT.17.201541.